SCHEMBL24257594

SCHEMBL24257594

CCOC(=O)CNC(=O)c1ncc(-c2cnn(C3CCOCC3)c2)c(C)c1OCc1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 2/20 0.38
PRKAB2 O43741 1/20 0.38
ABL1 P00519 1/20 0.38
CSF1R P07333 1/20 0.38
LYN P07948 1/20 0.38
TGFBR1 P36897 1/20 0.38
PRKAG1 P54619 1/20 0.38
SIK1 P57059 1/20 0.38
PRKAA1 Q13131 1/20 0.38
SIK2 Q9H0K1 1/20 0.38
SIK3 Q9Y2K2 1/20 0.38
USP28 Q96RU2 1/20 0.37
USP25 Q9UHP3 1/20 0.37
AXL P30530 3/20 0.37
MERTK Q12866 3/20 0.37
CTSS P25774 1/20 0.36
ALK Q9UM73 1/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257712 0.87 MEN1 (0.48) KMT2AMEN1L3MBTL1
SCHEMBL30452371 0.87 MEN1 (0.48) KMT2AMEN1L3MBTL1
SCHEMBL24257689 0.86 IRAK4 (0.44) IRAK4AXLMERTKALKMAP4K3
SCHEMBL24257746 0.85 ABL1 (0.40) IRAK4PRKAB2ABL1CSF1RLYN
Glycine SCHEMBL30546830 0.85 IRAK4 (0.39) IRAK4USP28USP25AXLMERTK
Nitrous Acid SCHEMBL29248905 0.84 IRAK4 (0.42) IRAK4USP28USP25AXLMERTK
Glycine SCHEMBL29248906 0.83 IRAK4 (0.41) IRAK4USP28USP25AXLMERTK
SCHEMBL24257745 0.82 GRM4 (0.42) KMT2AMEN1L3MBTL1ALDH1A1RIPK2
SCHEMBL29248903 0.82 IRAK4 (0.41) IRAK4USP28USP25AXLMERTK
SCHEMBL24257538 0.82 KMT2A (0.39) KMT2AMEN1L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 IRAK4 133/4885PRKAB2 3124/4885ABL1 1142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.